Next-gen breast cancer drug, pneumococcal vaccine to come
By | translator Alice Kang
22.07.06 06:20:51
가나다라
0
Next-gen ADC ‘Enhertu’ being reviewed for approval… public petition filed for its entry
MSD challenges Pfizer with its 15-valent vaccine
2nd EGFR Exon 20 targeted therapy and first dual inhibitor for ocular disease await entry to Korea
New big drugs, including a pneumococcal vaccine, a macular degeneration treatment, and a breast cancer treatment, are expected to receive approval from the Ministry of Food and Drug Safety in the second half of this year.
According to industry sources on the 6th, new drugs such as ▲Vaxneuvance (MSD) ▲Enhertu (Daiichi Sankyo) ▲Vabysmo (Roche) ▲Nexviazyme (Sanofi) ▲Exkivity (Takeda Pharmaceutical) may be approved within the year. 18 drugs from 14 companies have been approved as new drugs in the first half of this year.
◆’Enhertu’ acclaimed at ASCO, makes the first step in HER2 positive breast cancer
▲Pic of Enhertu
AstraZeneca and Daiichi Sankyo’s breast cancer trea
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)